Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0QBQKB)
| ADC Name |
EBC-129
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
EBC-129
Click to Show/Hide
|
|||||
| Organization |
A*STAR (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti N256-glycosylated CEACAM5 and CEACAM6 antibody
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5); Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18/21 years (US/Singapore); weight 40-120kg; advanced/metastatic solid tumors refractory to standard therapy; ECOG PS ≤2 (Part A) or 0-1 (Parts B-D); adequate hepatic/renal/bone marrow function per protocol.
|
||||
| Administration Dosage |
EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and Day 1 of each 21- or 28-Day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05701527 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC-129 As a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours | ||||
| Primary Endpoint |
Primary endpoints include SAE/TEAE incidence (pre-screening to EOS), MTD/RP2D determination (Parts A/B/D), and ORR assessment (Parts C/D per RECIST v1.1) over 2 years.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (DCR, DoR, TTP, PFS, OS), PK parameters (Cmax, Ctrough, AUC, Tmax, t1/2 for EBC-129/pembrolizumab), immunogenicity (ADA/neutralizing antibodies), and tumor response comparisons (Part A) evaluated over 3.3 years.
|
||||